论文部分内容阅读
目的 研究用流式细胞术免疫表型分析t(8;2 1) (q2 2 ;q2 2 )急性髓系白血病 (AML)的免疫表型特点。方法 采用常规细胞形态学 /细胞化学、流式细胞术间接免疫荧光标记技术和R显带核型分析 (MIC)进行分型 ,部分加用RT PCR检测AML1/ETO融合基因。结果 ① 2 94例初治AML患者中 ,6 4例t(8;2 1)AML ,占 2 1.8% ,在M2 中高达 5 4.7%。 6 4例t(8;2 1)AML中M2 占 81.3% ;②与对照组比较 ,t(8;2 1)AML高表达CD19和CD3 4,低表达CD3 3 (P <0 .0 0 1) ;③以 2 0 %阳性细胞作为阳性标准 ,CD19阳性率在AML为 13.6 % (2 94例中 40例 ) ,t(8;2 1)AML为 5 0 % (6 4例中 32例 ) ,显著高于无t(8;2 1)AML组的 3 5 % (2 30例中 8例 ) (P <0 .0 0 1) ;④在t(8;2 1)AML患者中 ,CD19+ 和 (或 )CD3 4+ 5 8例 (90 .6 % )、CD19-和 (或 )CD3 4-6例 (9.4% )。结论 t(8;2 1)AML特别是M2 /t(8;2 1)高表达CD19与CD3 4,CD19与t(8;2 1)密切相关 ,CD19是预测t(8;2 1)的指标之一
Objective To investigate the immunophenotypic characteristics of t(8;21)(q22;q22) acute myeloid leukemia (AML) by flow cytometric immunophenotype. Methods Conventional cell morphology/cytochemistry, flow cytometry indirect immunofluorescence labeling and R-banding karyotype analysis (MIC) were used for typing, and partial RT PCR was used to detect AML1/ETO fusion gene. RESULTS Among the 94 patients with newly diagnosed AML, 64 patients had t(8;21) AML, accounting for 21.8%, and up to 5.7% in M2. M2 accounted for 81.3% in 64 patients with t(8;21) AML; 2 compared with the control group, t(8;21) AML highly expressed CD19 and CD3 4, and lowly expressed CD3 3 (P <0. 0 0 1 3) positive cells were 20% positive, CD19 positive rate in AML was 13.6% (40 cases in 2 94 cases), and t(8; 21) AML was 50% (32 cases in 64 cases). Significantly higher than 35% (8 cases in 2 of 30 cases) without t(8;21) AML group (P < 0.01); 4 in patients with t(8;21) AML, CD19+ And/or CD3 4+ 5 8 (90.6 %), CD19- and/or CD3 4-6 (9.4%). Conclusions t(8;21) AML, especially M2/t(8;21) is highly correlated with CD19 and CD3 4. CD19 is closely related to t(8;21), and CD19 is predictive of t(8;21). One of the indicators